The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study provided extensive data on predisposing factors, consequences, and prevention of atrial fibrillation (AF) in patients with hypertension and left ventricular (LV) hypertrophy. Randomized losartan-based treatment was superior to atenolol-based treatment for reducing new-onset AF and complications, especially stroke, associated with new-onset or pre-existing AF. Potential mechanisms of AF prevention by angiotensin receptor blockade supported by LIFE results include greater reduction in left atrial size and LV hypertrophy. Differential effects of antihypertensive treatment on the left atrium and left ventricle may help prevent AF and reduce risk of stroke associated with hypertensive heart disease.

[1]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[2]  A. Zanchetti,et al.  Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial , 2008, Journal of hypertension.

[3]  C. Meuleman.  Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. The ONTARGET Investigators. , 2008 .

[4]  K. Furie,et al.  Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2008, Circulation.

[5]  A. Dominiczak,et al.  2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. , 2007, Journal of hypertension.

[6]  M. Hennersdorf,et al.  Prevalence of Paroxysmal Atrial Fibrillation Depending on the Regression of Left Ventricular Hypertrophy in Arterial Hypertension , 2007, Hypertension Research.

[7]  J. Seward,et al.  Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. , 2007, Journal of the American College of Cardiology.

[8]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[9]  R. Devereux,et al.  Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study , 2007, Current medical research and opinion.

[10]  W. Mello.  Chronic blockade of angiotensin II AT1-receptors increased cell-to-cell communication, reduced fibrosis and improved impulse propagation in the failing heart. , 2006 .

[11]  M. Olsen,et al.  Abstract 3701: Better Preservation of Left Atrial Systolic Force By Losartan may Contribute to Lower Incidence of New-onset Atrial Fibrillation: The LIFE study , 2006 .

[12]  Sverker Jern,et al.  Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. , 2006, JAMA.

[13]  R. Devereux,et al.  Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation , 2006, Current cardiology reports.

[14]  Silvia G. Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text , 2006 .

[15]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[16]  P. Wolf,et al.  Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2006, Circulation.

[17]  R. Devereux,et al.  Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS). , 2006, American heart journal.

[18]  R. Fogari,et al.  Losartan and Prevention of Atrial Fibrillation Recurrence in Hypertensive Patients , 2006, Journal of cardiovascular pharmacology.

[19]  J. Ruskin,et al.  Economic burden and co‐morbidities of atrial fibrillation in a privately insured population , 2005, Current medical research and opinion.

[20]  S. Yusuf,et al.  Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. , 2005, Journal of the American College of Cardiology.

[21]  M. Nieminen,et al.  Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. , 2005, Journal of the American College of Cardiology.

[22]  M. Nieminen,et al.  Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. , 2005, Journal of the American College of Cardiology.

[23]  Katherine E. Harris,et al.  Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study , 2005, Hypertension.

[24]  M. Nieminen,et al.  Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial , 2004, Circulation.

[25]  M. Nieminen,et al.  Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy , 2004, Journal of hypertension.

[26]  R. Devereux,et al.  Diuretics in the LIFE study , 2004, The Lancet.

[27]  J. Edelman,et al.  Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study , 2004, Journal of Human Hypertension.

[28]  Marylyn D Ritchie,et al.  Renin-Angiotensin System Gene Polymorphisms and Atrial Fibrillation , 2004, Circulation.

[29]  M. Nieminen,et al.  Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study , 2003, Circulation.

[30]  R. Schmieder,et al.  A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. , 2003, The American journal of medicine.

[31]  K. Arakawa,et al.  Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. , 2003, Journal of the American College of Cardiology.

[32]  Maurizio Bentivoglio,et al.  Atrial Fibrillation in Hypertension: Predictors and Outcome , 2003, Hypertension.

[33]  Richard B. Devereux,et al.  Correlates of Left Atrial Size in Hypertensive Patients With Left Ventricular Hypertrophy: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study , 2002, Hypertension.

[34]  M. Nieminen,et al.  Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. , 1998, Hypertension.

[35]  P A Wolf,et al.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. , 1998, The American journal of cardiology.

[36]  M. Nieminen,et al.  The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. , 1997, American journal of hypertension.

[37]  M. Nieminen,et al.  H35: Baseline characteristics of the life (Losartan intervention for endpoint reduction) in hypertension study , 1997 .

[38]  R B D'Agostino,et al.  Left atrial size and the risk of stroke and death. The Framingham Heart Study. , 1995, Circulation.

[39]  M. Quiñones,et al.  Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. , 1995, Circulation.

[40]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[41]  A. Belanger,et al.  The Framingham study. , 1976, British medical journal.

[42]  W. Elliott.  Left Atrial Size and Risk of Major Cardiovascular Events During Antihypertensive Treatment: Losartan Intervention for Endpoint Reduction in Hypertension Trial , 2008 .

[43]  A. Waldo.  Angiotensin II Receptor Blockade Reduces New-Onset Atrial Fibrillation and Subsequent Stroke Compared to Atenolol: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study , 2006 .

[44]  J. Halperin,et al.  Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. , 2000, Journal of the American College of Cardiology.

[45]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .